Skip to main content

Table 2 The CEUS features of included lesions

From: Comparison contrast-enhanced CT with contrast-enhanced US in diagnosing combined hepatocellular-cholangiocarcinoma: a propensity score-matched study

Imaging features

cHCC-CCAa

(n = 45)

HCC

(n = 90)

p value#

B-model ultrasound

Size (cm)

5.6 ± 3.5

5.8 ± 3.8

0.799

Number of tumors (single)

18 (40.0)

26 (28.9)

0.243

Cirrhosis

23 (51.1)

43 (47.8)

 

Nodule echo (hypo-)

40 (88.9)

68 (75.6)

0.109

Boundary (well)

13 (28.9)

35 (38.9)

0.170

Shape (regular)

16 (35.6)

45 (50.0)

0.143

CEUS

Enhancement level in the AP

  

1.000

 Hyperenhancement

44 (97.8)

89 (98.9)

 

 Isoenhancement

1 (2.2)

1 (1.1)

 

 Hypoenhancement

0 (0.0)

0 (0.0)

 

Enhancement level in the PVP

  

0.002

 Hyperenhancement

0 (0.0)

0 (0.0)

 

 Isoenhancement

5 (11.1)

32 (35.6)

 

 Hypoenhancement

40 (88.9)

58 (64.4)

 

Enhancement level in the LP

  

0.424

 Hyperenhancement

0 (0.0)

0 (0.0)

 

 Isoenhancement

1 (2.2)

6 (6.7)

 

 Hypoenhancement

44 (97.8)

84 (93.3)

 

LI-RADS major features

 Rim APHE

1 (2.3)

1 (1.1)

1.000

 Early washout

19 (42.4)

23 (25.6)

0.075

 Marked washout within two minutes

0 (0.0)

1 (1.1)

1.000

 Mild and late washout

44 (97.8)

84 (93.3)

1.000

 Tumor in vein

7 (15.6)

13 (14.4)

1.000

LI-RADS category

  

0.113

 LR-4

1 (2.2)

6 (6.7)

 

 LR-5

20 (44.4)

53 (58.9)

 

 LR-M

17 (37.8)

18 (20)

 

 LR-TIV

7 (15.6)

13 (14.4)

 

LI-RADS ancillary features

 Nodule-in-nodule architecture

0 (0.0)

0 (0.0)

NA

 Mosaic architecture

9 (20.0)

14 (15.6)

0.628

Other features

 Tumor supply artery

24 (53.3)

44 (48.9)

0.716

 Circumscribed enhancement (well)

20 (44.4)

45 (50.0)

0.587

 Unclear boundary in the intratumoral nonenhanced area

32 (71.1)

34 (37.8)

< 0.001

 Intratumoral vein in LP

12 (26.7)

17 (18.9)

0.206

 The proportion of washout (partial)

32 (71.1)

36 (40.0)

< 0.001

 Necrosis or severe ischemia

4 (8.9)

17 (18.9)

0.207

  1. cHCC-CCA combined hepatocellular-cholangiocarcinoma, HCC hepatocellular carcinoma, CEUS contrast-enhanced ultrasound, AP arterial phase, PVP portal venous phase, LP late phase, NA not available, APHE arterial phase hyperenhancement, LI-RADS liver imaging reporting and data system, LR liver imaging reporting and data system category
  2. #Categorical variables were compared by the χ2 test or Fisher’s exact test
  3. aUnless otherwise indicated, data are number of patients, with percentage in parentheses